1 completed, 1 not yet recruiting, 1 terminated. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Okyo Pharma Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of Urcosimod Ophthalmic Solution in Participants With Neuropathic Corneal Pain (NCP). Urcosimod ophthalmic solution is a preservative-free topical ophthalmic product; supplied in unit dose ampoules; administered QID for 12-weeks., Vehicle Ophthalmic Solution - Neuropathic Corneal Pain | Phase 3 | Not yet recruiting | Okyo Pharma Ltd | 111 | 2026-09-01 | 2026-09-29 |
| The Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects With Neuropathic Corneal Pain OK-101 0.05%, OK-101 0.1%, Placebo - Neuropathic Pain | Phase 2 | Terminated | Okyo Pharma Ltd | 18 | 2024-10-15 | 2025-08-15 |
| The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease OK-101, Placebo - Dry Eye Disease | Phase 2 | Completed | Okyo Pharma Ltd | 240 | 2023-04-28 | 2024-02-09 |
Dry Eye Syndromes (1) · Eye Pain (1) · Neuralgia (1)
United States (3)
Flavio Mantelli, MD, PhD (1) · Pedram Hamrah, MD (1) · Raj Patil, PhD (1)